Ruixin Medical Launches AngioQFA 100 at OCC 2025, Pioneering Integrated Epicardial and Microcirculatory Functional Assessment
RaysightMed
Medical Imaging Product Developer
On June 1, 2025, during the 19th Oriental Congress of Cardiology (OCC2025) held at the Shanghai World Expo Center,RaysightMed Grandly Held the "Macro Function, Micro Circulation" —— Coronary Artery Function Measurement System AngioQFA 100 Launch CeremonyProfessor Qian Juying, Vice President of Zhongshan Hospital Affiliated to Fudan University, led dozens of well-known experts from cardiovascular centers across China to witness this exciting moment.
In the keynote speech session, Professor Qian Juying delivered a speech titled "From the Updates of Guidelines and Evidence-based Evidence: A Look at Coronary Angiography."The Role of FFR in the Diagnosis and Treatment of Coronary Heart Disease -- A Keynote Speech on the Value of FFR and IMR. She pointed out: "Coronary blood flow is influenced by epicardial coronary arteries and intramyocardial microcirculation. In the past, solely assessing the degree of epicardial coronary stenosis had limitations. With the 2024 ESC guideline update on the definition of Chronic Coronary Syndrome (CCS), we need to reassess the pathogenesis of coronary heart disease and actively promoteThe Transformation of Traditional Diagnosis and Treatment Models for Coronary Heart Disease: From单纯的‘心外膜’冠脉功能学评估 to ‘Epicardial + Microcirculation’ Comprehensive Coronary Functional Assessment, Shifting from Ischemia to Atherosclerotic Coronary Artery Disease.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Functional assessment has always been based on the Fractional Flow Reserve (FFR).（Fractional flow reserve ,FFR)Based on pressure guidewire measurement as the gold standard for coronary heart disease diagnosis, its use is limited due to its invasive nature, long duration, and poor guidewire maneuverability. In recent years, some new technologies have emerged in the industry to empower clinical applications, such as throughAi、3D SimulationAndConnecting Sensor Chip Technology for Functional Assessment Based on Coronary AngiographyFFRMicrocirculationResistance Index(Index of Microcirculatory Resistance, IMR) Evaluation.Professor Qian Juying believes: "If these methods are measuredThe measured index is considered to have a good correlation with FFR measured by pressure wire, with minimal offset and high accuracy. It can be used to guide clinical diagnosis and treatment decisions. Its clinical value may surpass that of the pressure wire, and importantly, patients can significantly reduce medical costs.
As a one-stop coronary macro+ Micro-functional Assessment System, RaysightMed Coronary Functional Measurement System AngioQFA 100Integrating RaysightMed's self-developed AI, 3D simulation, and connected sensor chip technologies, it provides a one-stop solution for obtaining coronary FFR and IMR measurement analysis results, with capabilities for plaque stability assessment and surgical planning, offering precise guidance throughout the entire PCI procedure.At the same time, the RaysightMed Coronary Functional Measurement System AngioQFA 100 is equipped with a disposable invasive blood pressure sensor.Not only does it significantly improve calculation accuracy, but it also covers a richer variety of lesion types compared to similar products.Prospective clinical studies have shown that the FFR and IMR measurement results of RaysightMed's AngioQFA 100 Coronary Function Measurement System are in good agreement with invasive gold standard results, with accuracy, sensitivity, and specificity all exceeding 95%, leading the industry and providing clinical support that is more reliable, precise, efficient, and comprehensive.
Founder and CEO of RaysightMedCEO Zheng Lingxiao stated that it is a great honor to officially release the Raysight Coronary Functional Assessment System AngioQFA 100 with the support and witness of numerous experts and partners. The application of each new technology cannot be achieved without the support of clinical experts, whose professional skills and clinical experience enable the technology to meet actual needs."The core advantage of RaysightMed isAchieved the industry's only fusion innovation of artificial intelligence and surgical robot technology., createdThe World's Only AI + Surgical Robot Precision Diagnosis and Treatment Platform for Cardiovascular and Cerebrovascular Diseases，Built a full-course precision diagnosis and treatment solution covering "preoperative assessment - intraoperative diagnosis and intelligent treatment - postoperative intelligent management.". This not only achieves industry-leading accuracy and efficiency in the diagnosis and treatment of coronary heart disease, but also covers a broader and more complex range of symptoms.In the future, RaysightMed looks forward to collaborating with more clinical experts and partners, ensuring that every blood vessel receives earlier diagnosis and more precise treatment, as we journey together into the vast expanse of precision medicine!"